Aytu BioPharma Q3 revenue falls amid EXXUA launch

Aytu Biopharma

13/05/2026 21:25

Overview

U.S. CNS drugmaker's fiscal Q3 revenue fell yr/yr but beat analyst expectations

Adjusted EBITDA swung to a loss for fiscal Q3 but beat analyst expectations

Revenue decline driven by lower ADHD and pediatric sales amid EXXUA launch focus and generic competition

Outlook

Company expects continued growth for EXXUA as awareness and utilization expand

Aytu to prioritize investment in EXXUA while maintaining profitability from legacy ADHD and Pediatric portfolios

Company sees ADHD portfolio remaining profitable despite generic competition and reduced marketing focus

Result Drivers

EXXUA LAUNCH - New antidepressant EXXUA contributed $2.4 mln in Q3 revenue, with rapid prescription growth following its formal launch in mid-January, per CEO Josh Disbrow

ADHD PORTFOLIO DECLINE - ADHD product revenue fell due to a shift in sales force focus to EXXUA and the introduction of generic competition, according to management

PEDIATRIC PORTFOLIO DECLINE - Pediatric product revenue dropped, attributed to payor changes impacting prescribing and an increase in returns, per management

Company press release: ID:nACSV2SrWa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$12.41 mln
$12.05 mln (3 Analysts)
Q3 EPS
-$0.53
Q3 Net Income
-$5.62 mln
Q3 Adjusted EBITDA
Beat
-$2.80 mln
-$5.05 mln (3 Analysts)
Q3 Gross Profit
$7.60 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Aytu Biopharma Inc is $7.00, about 204.3% above its May 12 closing price of $2.30

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)